{"protocolSection":{"identificationModule":{"nctId":"NCT00365378","orgStudyIdInfo":{"id":"V501-005"},"secondaryIdInfos":[{"id":"2006_515"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)","officialTitle":"Study of Pilot Manufacturing Lot of HPV 16 Virus-Like Particle (VLP) Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females"},"statusModule":{"statusVerifiedDate":"2015-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"1999-09"},"primaryCompletionDateStruct":{"date":"2004-03","type":"ACTUAL"},"completionDateStruct":{"date":"2009-07","type":"ACTUAL"},"studyFirstSubmitDate":"2006-08-16","studyFirstSubmitQcDate":"2006-08-16","studyFirstPostDateStruct":{"date":"2006-08-17","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-03-22","resultsFirstSubmitQcDate":"2010-03-22","resultsFirstPostDateStruct":{"date":"2010-04-09","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-10-22","lastUpdatePostDateStruct":{"date":"2015-10-23","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Subjects received HPV 16 L1 VLP vaccine or placebo (1:1 ratio). Endpoints included efficacy, immunogenicity, and safety."},"conditionsModule":{"conditions":["HPV 16 Infection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":2409,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","description":"HPV 16 L1 VLP vaccine","interventionNames":["Biological: Comparator: HPV 16 L1 Vaccine"]},{"label":"2","type":"PLACEBO_COMPARATOR","description":"Placebo","interventionNames":["Biological: Comparator: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Comparator: HPV 16 L1 Vaccine","description":"A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6","armGroupLabels":["1"],"otherNames":["V501"]},{"type":"BIOLOGICAL","name":"Comparator: Placebo","description":"A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6","armGroupLabels":["2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Persistent HPV 16 Infection","description":"Cases of persistent infection were those with detection of HPV 16 by PCR (Polymerase chain reaction) on at least 2 consecutive visits at least 4 months apart; or detection of HPV 16 in a cervical biopsy specimen showing pathologic evidence of CIN1 (Cervical intraepithelial neoplasia), CIN2 or CIN3 together with HPV 16 detected at the visit immediately before or after the biopsy; or detection of HPV 16 on a subject's last visit.","timeFrame":"Through Month 48"},{"measure":"Incidence of HPV 16-related CIN1, CIN2 or C1N3","description":"Cases of HPV 16-related CIN1, CIN2 or CIN3 are those with detection of HPV 16 in a cervical biopsy specimen showing pathologic evidence of CIN1, CIN2 or CIN3 together with HPV 16 detected at the visit immediately before or after the biopsy.","timeFrame":"Through Month 48"},{"measure":"Serum Anti-HPV 16 Geometric Mean Titers","description":"The limit of detection of the assay was 6 mMU/ml. Samples with titer below the limit of detection were assigned a value of 3 for calculation of GMT and confidence interval. GMTs and confidence limits below the limit of detection are shown as \"6.0\".","timeFrame":"Month 7"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy, unmarried females age 16 to 23 years with intact uteri\n* Not pregnant at enrollment\n* Agreed to use effective contraception through Month 7 of the study\n* A lifetime history of 0 to 5 male partners with whom the subjects engaged in at least one episode of insertive intercourse\n\nExclusion Criteria:\n\n* No prior history of Human Papillomavirus (HPV) vaccination\n* No receipt of any other vaccination within 1 month prior to enrollment or plans to receive any other vaccination within 1 month prior to or after any dose of study vaccine\n* No prior history of an abnormal Papanicolaou (Pap) test showing Squamous intraepithelial lesion (SIL) or biopsy showing Cervical intraepithelial neoplasia (CIN)","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"16 Years","maximumAge":"23 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"16394035","type":"BACKGROUND","citation":"Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006 Jan;107(1):18-27. doi: 10.1097/01.AOG.0000192397.41191.fb."},{"pmid":"12444178","type":"BACKGROUND","citation":"Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU; Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002 Nov 21;347(21):1645-51. doi: 10.1056/NEJMoa020586."},{"pmid":"18435868","type":"BACKGROUND","citation":"Paavonen J; Future II Study Group. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. Curr Med Res Opin. 2008 Jun;24(6):1623-34. doi: 10.1185/03007990802068151. Epub 2008 Apr 23."},{"pmid":"18313445","type":"BACKGROUND","citation":"Barr E, Gause CK, Bautista OM, Railkar RA, Lupinacci LC, Insinga RP, Sings HL, Haupt RM. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol. 2008 Mar;198(3):261.e1-11. doi: 10.1016/j.ajog.2007.09.001."},{"pmid":"17544766","type":"BACKGROUND","citation":"Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007 Jun 2;369(9576):1861-1868. doi: 10.1016/S0140-6736(07)60852-6."},{"pmid":"17445955","type":"BACKGROUND","citation":"Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007 May 22;25(21):4324-33. doi: 10.1016/j.vaccine.2007.02.069. Epub 2007 Mar 12."},{"pmid":"41276263","type":"DERIVED","citation":"Bergman H, Henschke N, Arevalo-Rodriguez I, Buckley BS, Crosbie EJ, Davies JC, Dwan K, Golder SP, Loke YK, Probyn K, Petkovic J, Villanueva G, Morrison J. Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. Cochrane Database Syst Rev. 2025 Nov 24;11(11):CD015364. doi: 10.1002/14651858.CD015364.pub2."},{"pmid":"22277329","type":"DERIVED","citation":"Wiley DJ, Masongsong EV, Lu S, Heather L S, Salem B, Giuliano AR, Ault KA, Haupt RM, Brown DR. Behavioral and sociodemographic risk factors for serological and DNA evidence of HPV6, 11, 16, 18 infections. Cancer Epidemiol. 2012 Jun;36(3):e183-9. doi: 10.1016/j.canep.2011.12.007. Epub 2012 Jan 25."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"HPV 16 L1 VLP (Group 1)","description":"The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2, and Month 6) with HPV (Human Papillomavirus) 16 Virus-Like Particle (VLP) Vaccine.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine from completion of the Vaccination Period at Month 7 through Month 48. (The Month 7 visit was to be scheduled to occur no earlier than 3 weeks and no later than 7 weeks following the Month 6 visit.)"},{"id":"FG001","title":"Placebo (Group 2)","description":"The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2, and Month 6) with placebo.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo from completion of the Vaccination Period at Month 7 through Month 48. (The Month 7 visit was to be scheduled to occur no earlier than 3 weeks and no later than 7 weeks following the Month 6 visit.)"},{"id":"FG002","title":"Extension","description":"This group includes 400 subjects who received Monovalent HPV 16 L1 VLP vaccine or placebo during the base study. This includes subjects who previously discontinued from the study."}],"periods":[{"title":"Vaccination (Day 1 to Month 7)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1204"},{"groupId":"FG001","numSubjects":"1205"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Entered Vaccination Period","achievements":[{"groupId":"FG000","numSubjects":"1193"},{"groupId":"FG001","numSubjects":"1198"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"993"},{"groupId":"FG001","numSubjects":"1038"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"211"},{"groupId":"FG001","numSubjects":"167"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Randomized Not Vaccinated","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"88"},{"groupId":"FG001","numSubjects":"75"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"44"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Follow-up (Month 7 Though Month 48)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"993"},{"groupId":"FG001","numSubjects":"1038"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"835"},{"groupId":"FG001","numSubjects":"836"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"158"},{"groupId":"FG001","numSubjects":"202"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Moved","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"67"},{"groupId":"FG001","numSubjects":"69"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"73"},{"groupId":"FG001","numSubjects":"104"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Extension","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"400"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"203"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"197"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Moved","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"8"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"57"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"98"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"31"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"HPV 16 L1 VLP (Group 1)","description":"The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2, and Month 6) with HPV (Human Papillomavirus) 16 Virus-Like Particle (VLP) Vaccine.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine from completion of the Vaccination Period at Month 7 through Month 48."},{"id":"BG001","title":"Placebo (Group 2)","description":"The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2, and Month 6) with placebo.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo from completion of the Vaccination Period at Month 7 through Month 48."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1204"},{"groupId":"BG001","value":"1205"},{"groupId":"BG002","value":"2409"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20.0","lowerLimit":"16","upperLimit":"25"},{"groupId":"BG001","value":"20.1","lowerLimit":"16","upperLimit":"23"},{"groupId":"BG002","value":"20.1","lowerLimit":"16","upperLimit":"25"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1204"},{"groupId":"BG001","value":"1205"},{"groupId":"BG002","value":"2409"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"142"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"94"},{"groupId":"BG001","value":"114"},{"groupId":"BG002","value":"208"}]}]},{"title":"Hispanic American","categories":[{"measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"93"},{"groupId":"BG002","value":"182"}]}]},{"title":"Native American","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"23"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"918"},{"groupId":"BG001","value":"889"},{"groupId":"BG002","value":"1807"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"47"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Persistent HPV 16 Infection","description":"Cases of persistent infection were those with detection of HPV 16 by PCR (Polymerase chain reaction) on at least 2 consecutive visits at least 4 months apart; or detection of HPV 16 in a cervical biopsy specimen showing pathologic evidence of CIN1 (Cervical intraepithelial neoplasia), CIN2 or CIN3 together with HPV 16 detected at the visit immediately before or after the biopsy; or detection of HPV 16 on a subject's last visit.","populationDescription":"Per-protocol population: subjects must have no major protocol violations, must be seronegative to HPV 16 at Day 1 and PCR (Polymerase chain reaction) negative to HPV 16 through Month 7, and must provide follow-up data after Month 7","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Incidence per 100 person-years","timeFrame":"Through Month 48","groups":[{"id":"OG000","title":"HPV 16 L1 VLP (Group 1)","description":"The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2, and Month 6) with HPV (Human Papillomavirus) 16 Virus-Like Particle (VLP) Vaccine.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine from completion of the Vaccination Period at Month 7 through Month 48."},{"id":"OG001","title":"Placebo (Group 2)","description":"The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2, and Month 6) with placebo.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo from completion of the Vaccination Period at Month 7 through Month 48."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"755"},{"groupId":"OG001","value":"750"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"4.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Vaccine Efficacy","paramValue":"94.3","ciPctValue":"95","ciLowerLimit":"87.8","ciUpperLimit":"97.7","estimateComment":"Vaccine Efficacy (% relative risk reduction)\n\nConfidence Interval based on binomial tail probabilities and not from a dispersion parameter."}]},{"type":"PRIMARY","title":"Incidence of HPV 16-related CIN1, CIN2 or C1N3","description":"Cases of HPV 16-related CIN1, CIN2 or CIN3 are those with detection of HPV 16 in a cervical biopsy specimen showing pathologic evidence of CIN1, CIN2 or CIN3 together with HPV 16 detected at the visit immediately before or after the biopsy.","populationDescription":"Per-protocol population: subjects must have no major protocol violations, must be seronegative to HPV 16 at Day 1 and PCR negative to HPV 16 through Month 7, and must provide follow-up data after Month 7","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Incidence per 100 person-years","timeFrame":"Through Month 48","groups":[{"id":"OG000","title":"HPV 16 L1 VLP (Group 1)","description":"The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2, and Month 6) with HPV (Human Papillomavirus) 16 Virus-Like Particle (VLP) Vaccine.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine from completion of the Vaccination Period at Month 7 through Month 48."},{"id":"OG001","title":"Placebo (Group 2)","description":"The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2, and Month 6) with placebo.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo from completion of the Vaccination Period at Month 7 through Month 48."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"755"},{"groupId":"OG001","value":"750"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"1.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Vaccine Efficacy","paramValue":"100.0","ciPctValue":"95","ciLowerLimit":"84.0","ciUpperLimit":"100.0","estimateComment":"Vaccine Efficacy (% relative risk reduction)\n\nConfidence Interval based on binomial tail probabilities and not from a dispersion parameter."}]},{"type":"PRIMARY","title":"Serum Anti-HPV 16 Geometric Mean Titers","description":"The limit of detection of the assay was 6 mMU/ml. Samples with titer below the limit of detection were assigned a value of 3 for calculation of GMT and confidence interval. GMTs and confidence limits below the limit of detection are shown as \"6.0\".","populationDescription":"Per-protocol population: subjects must have no major protocol violations, must be seronegative to HPV 16 at Day 1 and PCR negative to HPV 16 through Month 7, and must provide serology data at Month 7","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"milliMerck units/ml (mMU/ml)","timeFrame":"Month 7","groups":[{"id":"OG000","title":"HPV 16 L1 VLP (Group 1)","description":"The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2, and Month 6) with HPV (Human Papillomavirus) 16 Virus-Like Particle (VLP) Vaccine.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the HPV 16 VLP Vaccine from completion of the Vaccination Period at Month 7 through Month 48."},{"id":"OG001","title":"Placebo (Group 2)","description":"The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2, and Month 6) with placebo.\n\nThe Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo from completion of the Vaccination Period at Month 7 through Month 48."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"684"},{"groupId":"OG001","value":"680"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1518.8","lowerLimit":"1385.5","upperLimit":"1665.0"},{"groupId":"OG001","value":"6.0","lowerLimit":"6.0","upperLimit":"6.0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events (AEs) were collected from Day 1 until Month 7. No non-serious AEs were collected and no Vaccination Report Card (VRCs) were used in the extension study, therefore no data is entered for that group in the Other Adverse Events table.","description":"Subjects were observed for at least 20 minutes after each vaccination for any immediate reaction. Subjects were prompted to report temperatures and local (i.e., injection site) AEs for 5 days following each injection. Data on all other AEs were collected and recorded on the subject's vaccine report card for 14 days after each vaccination visit.","eventGroups":[{"id":"EG000","title":"HPV 16 L1 VLP (Group 1)","description":"The number of subjects who actually received the vaccine material corresponding to the indicated vaccination group. There was one subject randomized to the HPV 16 L1 VLP vaccine group who received placebo and then discontinued study participation. There was 1 subject randomized to the placebo group who received one vaccination of HPV 16 L1 VLP vaccine and then discontinued study participation. These 2 subjects were included in the counts reported in the Adverse Event tables. There were 2 subjects randomized to the HPV 16 L1 VLP vaccine group and 2 subjects randomized to the placebo group and who received mixed vaccine material. These 4 subjects were not included in the counts reported in this table. Therefore, this table reports N=1191 (1193 minus 2) subjects vaccinated with HPV 16 L1 VLP vaccine and N=1196 (1198 minus 2) subjects vaccinated with placebo.","seriousNumAffected":19,"seriousNumAtRisk":1191,"otherNumAffected":1025,"otherNumAtRisk":1191},{"id":"EG001","title":"Placebo (Group 2)","description":"The number of subjects who actually received the vaccine material corresponding to the indicated vaccination group. There was one subject randomized to the HPV 16 L1 VLP vaccine group who received placebo and then discontinued study participation. There was 1 subject randomized to the placebo group who received one vaccination of HPV 16 L1 VLP vaccine and then discontinued study participation. These 2 subjects were included in the counts reported in the Adverse Event tables. There were 2 subjects randomized to the HPV 16 L1 VLP vaccine group and 2 subjects randomized to the placebo group and who received mixed vaccine material. These 4 subjects were not included in the counts reported in this table. Therefore, this table reports N=1191 (1193 minus 2) subjects vaccinated with HPV 16 L1 VLP vaccine and N=1196 (1198 minus 2) subjects vaccinated with placebo.","seriousNumAffected":20,"seriousNumAtRisk":1196,"otherNumAffected":1013,"otherNumAtRisk":1196},{"id":"EG002","title":"Extension","description":"This group includes 400 subjects who received Monovalent HPV 16 L1 VLP vaccine or placebo during the base study. This includes subjects who previously discontinued from the study.","seriousNumAffected":1,"seriousNumAtRisk":400,"otherNumAffected":0,"otherNumAtRisk":0}],"seriousEvents":[{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Alcohol poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Back injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":2,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Multiple injuries","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Nerve injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Pelvic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Radial nerve injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":2,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Urinary bladder rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Arthropathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Limb deformity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Perineal laceration","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Aggression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Anxiety disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Bulimia nervosa","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":2,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Mania","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1191},{"groupId":"EG001","numAffected":2,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Dysfunctional uterine bleeding","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Ovarian cyst ruptured","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":1,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1191},{"groupId":"EG001","numAffected":0,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":400}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":91,"numAtRisk":1191},{"groupId":"EG001","numAffected":95,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":59,"numAtRisk":1191},{"groupId":"EG001","numAffected":64,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":85,"numAtRisk":1191},{"groupId":"EG001","numAffected":88,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":53,"numAtRisk":1191},{"groupId":"EG001","numAffected":62,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":499,"numAtRisk":1191},{"groupId":"EG001","numAffected":495,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":68,"numAtRisk":1191},{"groupId":"EG001","numAffected":65,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Injection Site Erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":335,"numAtRisk":1191},{"groupId":"EG001","numAffected":286,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Injection Site Haematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":69,"numAtRisk":1191},{"groupId":"EG001","numAffected":61,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Injection Site Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":951,"numAtRisk":1191},{"groupId":"EG001","numAffected":924,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Injection Site Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":288,"numAtRisk":1191},{"groupId":"EG001","numAffected":211,"numAtRisk":1196},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Of note, the number of subjects reported in the results posting is slightly different than that specified in the publication by Koutsky, et al (2002). The data provided here is based on final data."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"interventionBrowseModule":{"meshes":[{"id":"D000068857","term":"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18"}],"ancestors":[{"id":"D017778","term":"Vaccines, Combined"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D053918","term":"Papillomavirus Vaccines"},{"id":"D014765","term":"Viral Vaccines"}]}},"hasResults":true}